X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (6075) 6075
Publication (464) 464
Book Review (119) 119
Newspaper Article (27) 27
Book Chapter (20) 20
Book / eBook (15) 15
Newsletter (12) 12
Magazine Article (8) 8
Conference Proceeding (7) 7
Dissertation (6) 6
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (5661) 5661
female (5482) 5482
endometrial cancer (2864) 2864
index medicus (2829) 2829
oncology (2820) 2820
middle aged (2415) 2415
cancer (2029) 2029
endometrial neoplasms - pathology (1826) 1826
aged (1821) 1821
obstetrics & gynecology (1794) 1794
endometrial neoplasms - drug therapy (1781) 1781
adult (1654) 1654
carcinoma (1193) 1193
chemotherapy (802) 802
breast neoplasms - drug therapy (786) 786
breast-cancer (779) 779
endometrial neoplasms - metabolism (777) 777
risk factors (740) 740
neoplasm staging (732) 732
animals (727) 727
prognosis (717) 717
cell line, tumor (715) 715
care and treatment (681) 681
aged, 80 and over (677) 677
breast cancer (642) 642
research (628) 628
endometrial neoplasms - genetics (620) 620
treatment outcome (595) 595
tamoxifen (587) 587
women (586) 586
endometrial carcinoma (583) 583
expression (575) 575
obstetrics and gynecology (570) 570
health aspects (565) 565
endometrial neoplasms - surgery (551) 551
therapy (550) 550
risk (543) 543
postmenopausal women (538) 538
ovarian cancer (537) 537
retrospective studies (534) 534
tamoxifen - adverse effects (533) 533
endometrial neoplasms - chemically induced (530) 530
antineoplastic combined chemotherapy protocols - therapeutic use (509) 509
hematology, oncology and palliative medicine (497) 497
tamoxifen - therapeutic use (490) 490
analysis (488) 488
estrogen (485) 485
tumors (485) 485
antineoplastic agents, hormonal - therapeutic use (481) 481
adenocarcinoma (464) 464
endometrium (454) 454
apoptosis (431) 431
chemotherapy, adjuvant (406) 406
gynecologic-oncology-group (399) 399
immunohistochemistry (397) 397
hysterectomy (384) 384
survival (384) 384
mice (383) 383
endometrium - pathology (382) 382
follow-up studies (371) 371
surgery (370) 370
antineoplastic agents - therapeutic use (368) 368
metastasis (367) 367
ovarian neoplasms - drug therapy (363) 363
male (341) 341
adenocarcinoma - drug therapy (340) 340
adenocarcinoma - pathology (332) 332
endometrium - drug effects (325) 325
drug therapy (319) 319
antineoplastic agents, hormonal - adverse effects (318) 318
endometrial neoplasms - epidemiology (318) 318
article (314) 314
endometrial neoplasms - mortality (313) 313
medicine & public health (311) 311
survival rate (311) 311
oncology, experimental (309) 309
pathology (306) 306
cell proliferation - drug effects (303) 303
cisplatin (303) 303
postmenopause (301) 301
radiotherapy (299) 299
ovarian-cancer (287) 287
neoplasm recurrence, local - drug therapy (286) 286
ovarian neoplasms - pathology (286) 286
disease-free survival (284) 284
cell biology (278) 278
apoptosis - drug effects (277) 277
hormone replacement therapy (277) 277
endometrial neoplasms - diagnosis (275) 275
gene expression (273) 273
genetic aspects (272) 272
endocrinology & metabolism (270) 270
endometrial neoplasms - therapy (270) 270
menopause (270) 270
development and progression (268) 268
tumor cells, cultured (266) 266
endometrial neoplasms - radiotherapy (265) 265
combined modality therapy (260) 260
antineoplastic agents - pharmacology (257) 257
mutation (251) 251
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (5823) 5823
French (59) 59
Japanese (59) 59
German (57) 57
Russian (42) 42
Chinese (37) 37
Polish (16) 16
Spanish (16) 16
Italian (14) 14
Bulgarian (13) 13
Portuguese (6) 6
Hebrew (5) 5
Czech (3) 3
Hungarian (3) 3
Swedish (3) 3
Danish (2) 2
Bosnian (1) 1
Dutch (1) 1
Norwegian (1) 1
Romanian (1) 1
Serbian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Clinical Oncology, ISSN 0732-183X, 12/2015, Volume 33, Issue 34, pp. 4015 - 4022
Journal Article
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 08/2014, Volume 16, Issue 8, pp. 707 - 710
Journal Article
PLoS ONE, ISSN 1932-6203, 12/2015, Volume 10, Issue 12, p. e0145754
Background High-grade serous ovarian and endometrial cancers are the most lethal female reproductive tract malignancies worldwide. In part, failure to treat... 
CA-125 | MULTIDISCIPLINARY SCIENCES | EPITHELIAL OVARIAN-CANCER | Endometrial Neoplasms - mortality | Humans | Middle Aged | Ovarian Neoplasms - mortality | Genital Neoplasms, Female - drug therapy | DNA, Neoplasm - blood | Endometrial Neoplasms - genetics | Adult | Female | Neoplasm Recurrence, Local - blood | Ovarian Neoplasms - drug therapy | Genital Neoplasms, Female - genetics | CA-125 Antigen - blood | Ovarian Neoplasms - blood | Genital Neoplasms, Female - blood | Mutation - genetics | Breast Neoplasms - drug therapy | Biomarkers, Tumor - blood | Genital Neoplasms, Female - mortality | Exome - genetics | Breast Neoplasms - genetics | Breast Neoplasms - blood | Breast Neoplasms - mortality | Endometrial Neoplasms - drug therapy | Neoplasm Recurrence, Local - genetics | Aged | Biomarkers, Tumor - genetics | DNA, Neoplasm - genetics | Endometrial Neoplasms - blood | Physiological aspects | Prognosis | Biological markers | Genital cancer | Tumors | Plasma | Scanning | Ovarian carcinoma | Medical services | Fallopian tube | Cancer therapies | Ovarian cancer | Gene sequencing | Computed tomography | Surgery | Quality | Imaging | Bioindicators | Endometrium | Deoxyribonucleic acid--DNA | DNA probes | Gynecology | Breast cancer | Patients | Survival | Obstetrics | Medicine | Lead time | Chemotherapy | Surveillance | Womens health | Biomarkers | Diagnostic systems | Mutation | Reproductive system | Uterine cancer | Peritoneum | Cancer | Deoxyribonucleic acid | DNA
Journal Article
Nature Reviews Clinical Oncology, ISSN 1759-4774, 05/2011, Volume 8, Issue 5, pp. 302 - 306
Journal Article
Cancer, ISSN 0008-543X, 08/2017, Volume 123, Issue 16, pp. 3080 - 3087
BACKGROUND Mirvetuximab soravtansine (IMGN853) is an antibody‐drug conjugate that selectively targets folate receptor α (FRα). In this phase 1 dose‐escalation... 
clinical trial | targeted therapy | folate receptor | phase 1 | antibody‐drug conjugate | antibody-drug conjugate | THERAPEUTICS | FARLETUZUMAB | PLATINUM-RESISTANT OVARIAN | MONOCLONAL-ANTIBODY | COMBINATION | EPITHELIAL OVARIAN-CANCER | CHEMOTHERAPY | DELIVERY | THERAPY | ONCOLOGY | PROTEINS | Lung Neoplasms - drug therapy | Humans | Middle Aged | Ovarian Neoplasms - pathology | Lung Neoplasms - pathology | Male | Antineoplastic Agents - therapeutic use | Fatigue - chemically induced | Diarrhea - chemically induced | Dose-Response Relationship, Drug | Vision Disorders - chemically induced | Aged, 80 and over | Immunoconjugates - therapeutic use | Adult | Female | Hypophosphatemia - chemically induced | Carcinoma, Renal Cell - drug therapy | Ovarian Neoplasms - drug therapy | Carcinoma, Non-Small-Cell Lung - pathology | Neoplasms, Glandular and Epithelial - pathology | Antibodies, Monoclonal, Humanized - therapeutic use | Carcinoma, Renal Cell - pathology | Maytansine - analogs & derivatives | Keratitis - chemically induced | Maytansine - therapeutic use | Disease Progression | Neoplasms - drug therapy | Maximum Tolerated Dose | Neoplasms, Glandular and Epithelial - drug therapy | Carcinoma, Ovarian Epithelial | Endometrial Neoplasms - drug therapy | Endometrial Neoplasms - pathology | Kidney Neoplasms - pathology | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Kidney Neoplasms - drug therapy | Neoplasms - pathology | Cancer patients | Care and treatment | Pharmacokinetics | Health aspects | Analysis | Ovarian cancer | Index Medicus | Abridged Index Medicus
Journal Article
by Dowsett, M and Forbes, J. F and Bradley, R and Ingle, J and Aihara, T and Bliss, J and Boccardo, F and Coates, A and Coombes, R. C and Cuzick, J and Dubsky, P and Gnant, M and Kaufmann, M and Kilburn, L and Perrone, F and Rea, D and Thurlimann, B and van de Velde, C and Pan, H and Peto, R and Davies, C and Gray, R and Burrett, J and Clarke, M and Duane, F and Evans, V and Gettins, L and Godwin, J and Liu, H and McGale, P and MacKinnon, E and McHugh, T and James, S and Morris, P and Read, S and Taylor, C and Wang, Y and Wang, Z and Bergh, J and Pritchard, K and Albain, K and Anderson, S and Arriagada, R and Barlow, W and Bergsten-Nordstrom, E and Buyse, M and Cameron, D and Coleman, R and Correa, C and Costantino, J and Davidson, N and Di Leo, A and Ewertz, M and Forbes, J and Gelber, R and Geyer, C and Gianni, L and Goldhirsch, A and Hayes, D and Hill, C and Janni, W and Martin, M and Norton, L and Ohashi, Y and Paik, S and Perez, E and Piccart, M and Pierce, L and Raina, V and Ravdin, P and Robertson, J and Rutgers, E and Sparano, J and Swain, S and Viale, G and von Minckwitz, G and Wang, X and Whelan, T and Wilcken, N and Winer, E and Wolmark, N and Wood, W and Abe, O and Abe, R and Enomoto, K and Kikuchi, K and Koyama, H and Masuda, H and Nomura, Y and Sakai, K and Sugimachi, K and Toi, M and Tominaga, T and Uchino, J and Yoshida, M and Haybittle, J. L and Leonard, C. F and Calais, G and Garaud, P and Collett, V and ... and Early Breast Canc Trialists and Early Breast Cancer Trialists' Collaborative Group (EBCTCG)
Lancet, The, ISSN 0140-6736, 2015, Volume 386, Issue 10001, pp. 1341 - 1352
Journal Article
Annals of Surgical Oncology, ISSN 1068-9265, 12/2012, Volume 19, Issue 13, pp. 4059 - 4067
To analyze the impact of radical cytoreductive surgery—as part of primary tumor debulking—on the amount of residual tumor and survival in patients with... 
Oncology | Medicine & Public Health | Surgical Oncology | Surgery | SURGERY | PROGNOSTIC-FACTOR | ONCOLOGY | RESECTION | CARCINOMA | Prognosis | Follow-Up Studies | Neoplasm, Residual - surgery | Endometrial Neoplasms - mortality | Adenocarcinoma, Clear Cell - mortality | Humans | Middle Aged | Neoplasm Recurrence, Local - drug therapy | Gynecologic Surgical Procedures | Ovarian Neoplasms - mortality | Neoplasm Recurrence, Local - mortality | Cystadenocarcinoma, Serous - drug therapy | Neoplasm Recurrence, Local - surgery | Peritoneal Neoplasms - drug therapy | Neoplasm Grading | Adenocarcinoma, Mucinous - surgery | Adult | Female | Neoadjuvant Therapy | Chemotherapy, Adjuvant | Neoplasm, Residual - mortality | Adenocarcinoma, Mucinous - drug therapy | Ovarian Neoplasms - drug therapy | Adenocarcinoma, Clear Cell - surgery | Peritoneal Neoplasms - surgery | Survival Rate | Combined Modality Therapy | Lymphatic Metastasis | Peritoneal Neoplasms - mortality | Cystadenocarcinoma, Serous - surgery | Adenocarcinoma, Mucinous - mortality | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Endometrial Neoplasms - surgery | Neoplasm, Residual - drug therapy | Cystadenocarcinoma, Serous - mortality | Endometrial Neoplasms - drug therapy | Aged | Neoplasm Staging | Adenocarcinoma, Clear Cell - drug therapy | Ovarian Neoplasms - surgery | Chemotherapy | Analysis | Ovarian cancer | Cancer
Journal Article
Journal of the National Cancer Institute, ISSN 0027-8874, 2011, Volume 103, Issue 17, pp. 1299 - 1309
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 04/2013, Volume 31, Issue 12, pp. 1554 - 1561
Journal Article
by Xiang, Y and Ma, N and Wang, D and Zhang, Y and Zhou, J and Wu, G and Zhao, R and Huang, H and Wang, X and Qiao, Y and Li, F and Han, D and Wang, L and Zhang, G and Gao, X
Oncogene, ISSN 0950-9232, 01/2014, Volume 33, Issue 3, pp. 378 - 386
Epithelial ovarian cancer (EOC) is a highly lethal gynaecological malignancy. Cisplatin is the basal chemotherapeutic agent used to treat EOC, but resistance... 
microRNA | DNMT1 | decitabine | ovarian cancer | cisplatin resistance | METHYLATION | BIOCHEMISTRY & MOLECULAR BIOLOGY | DRUG-RESISTANCE | PLATINUM-RESISTANT | LINES | ENDOMETRIAL CANCER | CELL BIOLOGY | BREAST-CANCER | DNA METHYLTRANSFERASE 1 | IN-VITRO | HEPATOCELLULAR-CARCINOMA | ONCOLOGY | GENETICS & HEREDITY | GENE-EXPRESSION | Apoptosis - drug effects | Humans | Ovarian Neoplasms - pathology | Apoptosis - genetics | DNA (Cytosine-5-)-Methyltransferases - metabolism | Ovarian Neoplasms - genetics | Neoplasms, Glandular and Epithelial - genetics | Female | Antineoplastic Agents - pharmacology | Epigenesis, Genetic - drug effects | Ovarian Neoplasms - drug therapy | Neoplasms, Glandular and Epithelial - pathology | DNA (Cytosine-5-)-Methyltransferase 1 | Azacitidine - analogs & derivatives | Cisplatin - pharmacology | Reverse Transcriptase Polymerase Chain Reaction | Xenograft Model Antitumor Assays - methods | Blotting, Western | Hep G2 Cells | Azacitidine - pharmacology | DNA (Cytosine-5-)-Methyltransferases - genetics | Drug Resistance, Neoplasm - genetics | Animals | Mice, Nude | Neoplasms, Glandular and Epithelial - drug therapy | Cell Line, Tumor | Cell Proliferation - drug effects | Mice | MicroRNAs - genetics | Care and treatment | MicroRNA | Oncology, Experimental | Genetic aspects | Research | Identification and classification | Ovarian cancer | Cancer | Epigenetics | Sensitivity analysis
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 09/2013, Volume 19, Issue 18, pp. 5227 - 5239
Purpose: The aim of this study was to identify and validate novel predictive and/or prognostic serum proteomic biomarkers in patients with epithelial ovarian... 
PHASE-III TRIAL | BREAST-CANCER | MESOTHELIN | ONCOLOGY-GROUP | THERAPY | ONCOLOGY | METASTATIC COLORECTAL-CANCER | RENAL-CELL CARCINOMA | PLUS BEVACIZUMAB | CHEMOTHERAPY | ENDOTHELIAL GROWTH-FACTOR | Prognosis | Follow-Up Studies | Endometrial Neoplasms - mortality | Peritoneal Neoplasms - blood | Adenocarcinoma, Clear Cell - mortality | Humans | Middle Aged | Ovarian Neoplasms - mortality | Adenocarcinoma, Clear Cell - blood | Cystadenocarcinoma, Serous - drug therapy | Bevacizumab | Patient Selection | Fallopian Tube Neoplasms - blood | Peritoneal Neoplasms - drug therapy | Adenocarcinoma, Mucinous - blood | Angiogenesis Inhibitors - therapeutic use | Chromatography, Liquid | Adult | Female | Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | Adenocarcinoma, Mucinous - drug therapy | Ovarian Neoplasms - drug therapy | Fallopian Tube Neoplasms - drug therapy | Cystadenocarcinoma, Serous - blood | Antibodies, Monoclonal, Humanized - therapeutic use | Ovarian Neoplasms - blood | Survival Rate | Peritoneal Neoplasms - mortality | Biomarkers, Tumor - blood | Adenocarcinoma, Mucinous - mortality | Validation Studies as Topic | Fallopian Tube Neoplasms - mortality | Cystadenocarcinoma, Serous - mortality | Endometrial Neoplasms - drug therapy | Aged | Neoplasm Staging | Endometrial Neoplasms - blood | Adenocarcinoma, Clear Cell - drug therapy | Cohort Studies | bevacizumab | predictive | ICON7 | proteomics | serum | biomarkers
Journal Article